无机化学学报
無機化學學報
무궤화학학보
JOURNAL OF INORGANIC CHEMISTRY
2009年
6期
1077-1083
,共7页
黄娟%陈秋云%王玲昀%付海舰%李斌
黃娟%陳鞦雲%王玲昀%付海艦%李斌
황연%진추운%왕령윤%부해함%리빈
DNA%抗肿瘤%锌配合物%光谱
DNA%抗腫瘤%鋅配閤物%光譜
DNA%항종류%자배합물%광보
DNA%antieancer activity%zinc(Ⅱ) complex%spectroscopy
本文以N-烯丙基二吡啶甲基胺(Aldpa)和2,2-二(2-吡啶甲胺基)丙酸(Adpa)为配体,合成了2个锌配合物,并运用IR,UV,ES-MS等方法进行了表征.X-衍射晶体结构表明[(Adpa)Zn(CHCOO)]配合物中锌(Ⅱ)离子采取五配位三角双锥构型.紫外和荧光光谱滴定研究结果显示[(Adpa)Zn(CHCOO)]与ctDNA作用强于[(Aldpa)ZnCl2].用MTT法研究了配合物体外对肿瘤细胞生长的抑制作用.实验结果表明与ctDNA作用强的锌配合物抗肿瘤活性较好,二吡啶甲基胺氮原子上的取代基影响相应锌(Ⅱ)配合物的抗肿瘤活性.
本文以N-烯丙基二吡啶甲基胺(Aldpa)和2,2-二(2-吡啶甲胺基)丙痠(Adpa)為配體,閤成瞭2箇鋅配閤物,併運用IR,UV,ES-MS等方法進行瞭錶徵.X-衍射晶體結構錶明[(Adpa)Zn(CHCOO)]配閤物中鋅(Ⅱ)離子採取五配位三角雙錐構型.紫外和熒光光譜滴定研究結果顯示[(Adpa)Zn(CHCOO)]與ctDNA作用彊于[(Aldpa)ZnCl2].用MTT法研究瞭配閤物體外對腫瘤細胞生長的抑製作用.實驗結果錶明與ctDNA作用彊的鋅配閤物抗腫瘤活性較好,二吡啶甲基胺氮原子上的取代基影響相應鋅(Ⅱ)配閤物的抗腫瘤活性.
본문이N-희병기이필정갑기알(Aldpa)화2,2-이(2-필정갑알기)병산(Adpa)위배체,합성료2개자배합물,병운용IR,UV,ES-MS등방법진행료표정.X-연사정체결구표명[(Adpa)Zn(CHCOO)]배합물중자(Ⅱ)리자채취오배위삼각쌍추구형.자외화형광광보적정연구결과현시[(Adpa)Zn(CHCOO)]여ctDNA작용강우[(Aldpa)ZnCl2].용MTT법연구료배합물체외대종류세포생장적억제작용.실험결과표명여ctDNA작용강적자배합물항종류활성교호,이필정갑기알담원자상적취대기영향상응자(Ⅱ)배합물적항종류활성.
Two Zn(Ⅱ) complexes with Allyl bis(2-pyridylmethyl)amine (Aldpa), or bis(2-pyridylmethyl)amino-2-propionate(Adpa), were synthesized and characterized by IR, UV, ES-MS. The crystal structure shows that the Zn(Ⅱ) ion in [(Adpa)Zn(CHCOO)] is coordinated by three N atoms, one oxygen atom of the Adpa and one oxygen atom of CH3COO-, forming a distorted trigonal bipyramidal geometry. The spectrophotometric and fluorescence titration data indicate that the interaction between the [(Adpa)Zn(CHCOO)] with ct-DNA is more stronger than that of [(Aldpa)ZnCl2]. The [(Adpa)Zn(CH3COO)] is more active against the four cancer cells (Mcf-7, Eca-109, A549, Hela) than the [(Aldpa)ZnCl], indicating the antitumor activity of zinc(Ⅱ) complexes is dependent on its binding to DNA. The bioassay results also show that the substituents introduced on the secondary amino nitrogen atom of dpa have great contribution to the antitumor activities of these zinc(Ⅱ) complexes. Information obtained from the present is helpful to development of therapeutic agents. CCDC: 709681.